THE SMART SOLUTION FOR
BIOMARKER DISCOVERY & VALIDATION
Noble’s scientific team combines a deep understanding of cancer signaling pathways with public and proprietary genomic data across a compendium of cell lines and clinical samples to identify and validate biomarkers associated with drug response and efficacy.
For each project, a genotypically diverse cell line panel is selected for identification of candidate biomarkers associated with inhibition or resistance of the study drug across multiple indications. In silico profiling of the cell line panel is used to identify a molecular profile associated with sensitivity to the targeted drug.
Each cell line is treated with the study drug and analyzed with proprietary in vitro protein expression and genomic assays to further define the specific biomarkers of drug response and uncover possible new disease indications.
Noble’s expertise in animal models is then used to provide in vivo validation of pharmacodynamic markers and to characterize on-target dependencies of the client’s drug.
We have experience with a variety of mammalian species used for vaccine and drug development. Our studies range from single digit to hundreds of animals.
Our scientists, with over 15 years of GLP experience, provide all aspects of the GLP process from design to regulatory support of your IND, IDE or PMA FDA submission.